Alejandro Balsa
Overview
Explore the profile of Alejandro Balsa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
221
Citations
4542
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Novella-Navarro M, Van Den Rym A, Lopez-Pedrera C, Martinez-Feito A, Nieto-Carvalhal B, Reche K, et al.
Nutrients
. 2025 Mar;
17(5).
PMID: 40077690
: Obesity is a frequent comorbidity in rheumatoid arthritis (RA). This condition may lead these patients to have poorer disease control and a worse response to some of the available...
2.
Balsa A, Andreu J, Hermosa-Hernan J, Leon-Navarro J, Nicolas Pico J, Perez Venegas J, et al.
Reumatol Clin (Engl Ed)
. 2025 Feb;
21(1):101800.
PMID: 39894625
Introduction And Objectives: The SUMAR project aimed to establish a consensus on the concept of remission in patients with rheumatoid arthritis (RA) that takes into account the different perspectives of...
3.
Edwards C, Kronke G, Avouac J, Li Z, Conti F, Balsa A, et al.
J Rheumatol
. 2025 Jan;
PMID: 39814441
Objective: This study examined the effect of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once daily for up to 96...
4.
Monjo I, Nieto-Carvalhal B, Uyaguari M, Garcia-Carazo S, Balsa A, De Miguel E, et al.
Rheumatology (Oxford)
. 2025 Jan;
PMID: 39752328
Objectives: Giant cell arteritis (GCA) is a large/medium-vessel granulomatous vasculitis, and the PD-1/PD-L1 coinhibitory pathway seems to be implicated in its pathogenesis. CD4 T cells expressing high PD-1 levels, CD4+CXCR5-PD-1hi...
5.
Tornero C, De Miguel E, Navarro-Compan V, Balsa A, Aguado P
JBMR Plus
. 2024 Oct;
8(11):ziae124.
PMID: 39450343
Objectives: To estimate the prevalence of chondrocalcinosis and calcium pyrophosphate dihydrate deposition disease (CPPD) in patients with low alkaline phosphatase (ALP) levels and a positive genetic study (+GT) for hypophosphatasia...
6.
Taylor P, Feist E, Pope J, Nash P, Sibilia J, Caporali R, et al.
Ther Adv Musculoskelet Dis
. 2024 Oct;
16:1759720X241283340.
PMID: 39444594
Rheumatoid arthritis (RA) is an autoimmune disease characterised by persistent inflammation of the synovial joints as well as other tissues and organs. Left untreated, it can lead to joint damage,...
7.
Taylor P, Balsa A, Mongey A, Filkova M, Chebbah M, Le Clanche S, et al.
Rheumatol Ther
. 2024 Oct;
11(6):1425-1435.
PMID: 39397239
This commentary explores the potential cardiovascular (CV) benefits of combining methotrexate (MTX) and Janus kinase inhibitors (JAKis) in the treatment of rheumatoid arthritis (RA). While European guidelines recommend MTX as...
8.
Plasencia-Rodriguez C, Martinez-Feito A, Novella-Navarro M, de Diego R, Bonilla G, Gehin J, et al.
Front Med (Lausanne)
. 2024 Sep;
11:1461396.
PMID: 39296891
Background: The EXXELERATE study revealed poorer clinical outcomes in patients treated with adalimumab (ADL) and baseline rheumatoid factor (RF) above 203 IU/mL. However, responses were similar in patients treated with...
9.
Smolen J, Taylor P, Tanaka Y, Takeuchi T, Hashimoto M, Cara C, et al.
Rheumatology (Oxford)
. 2024 Sep;
63(11):3015-3024.
PMID: 39222436
Objectives: To assess the impact of baseline RF level on drug concentrations and efficacy of certolizumab pegol [CZP; TNF inhibitor (TNFi) without a crystallizable fragment (Fc)] and adalimumab (ADA; Fc-containing...
10.
Villalba A, Nuno L, Benito-Miguel M, Nieto-Carvalhal B, Monjo I, Novella-Navarro M, et al.
Rheumatology (Oxford)
. 2024 Aug;
PMID: 39141491
Objectives: A subset of human circulating FoxP3+ regulatory T cells expresses CD39 (cTreg39+) and hydrolyses pro-inflammatory adenine nucleotides released at inflammatory foci, rendering the anti-inflammatory agent adenosine. Methotrexate (MTX), inhibiting...